# Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD

> **NCT00446654** · PHASE1 · COMPLETED · sponsor: **Progen Pharmaceuticals** · enrollment: 43 (actual)

## Conditions studied

- Age Related Macular Degeneration

## Interventions

- **DRUG:** CGC-11047

## Key facts

- **NCT ID:** NCT00446654
- **Lead sponsor:** Progen Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2012-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00446654

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00446654, "Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT00446654. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*